Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CIP 321
Previous Study | Return to List | Next Study

Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03959423
Recruitment Status : Recruiting
First Posted : May 22, 2019
Last Update Posted : September 24, 2019
Sponsor:
Information provided by (Responsible Party):
Medtronic Diabetes

Brief Summary:
This study is a Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Device: AHCL insulin pump system Not Applicable

Detailed Description:
The purpose of this study is to evaluate the safety of the Advanced Hybrid Closed Loop system (AHCL) in type 1 diabetes adult and pediatric subjects in a home setting. The main objective in conducting this research is to collect data from patients who use the AHCL system at home, at work, at school and everywhere else.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Actual Study Start Date : June 7, 2019
Estimated Primary Completion Date : January 31, 2020
Estimated Study Completion Date : July 31, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Insulin

Arm Intervention/treatment
Experimental: Subjects 7-75 years of age
Subjects who have been diagnosed with type 1 diabetes
Device: AHCL insulin pump system
Advanced Hybrid Closed Loop insulin pump with associated CGM and blood glucose meter




Primary Outcome Measures :
  1. Change in HbA1c [ Time Frame: 3 months ]
    The overall mean difference of the change in HbA1c from baseline to end of 3-month study period.

  2. Change in percentage of Euglycemia [ Time Frame: 3 months ]
    The overall mean change in % of time in euglycemia (70-180 mg/dL) from baseline to the end of study will be estimated.


Secondary Outcome Measures :
  1. Number of Severe Hypoglycemic Event [ Time Frame: 3 months ]
    Number of severe hypoglycemic events occurred during 3-month period

  2. Number of Diabetic Ketoacidosis (DKA) Event [ Time Frame: 3 months ]
    Number of Diabetic Ketoacidosis (DKA) event occurred during 3-month period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is age 7-75 years at time of Screening
  2. Subjects 14-75 years of age: A clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  3. Subjects 7-13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis Study-specific inclusion criteria
  4. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily
  5. Subject is willing to perform required sensor calibrations
  6. Subject is willing to wear the system continuously throughout the study
  7. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units
  8. Subject has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central Lab) at time of Screening visit Note: All HbA1c blood specimens will be sent to and tested by a NGSP certified Central Laboratory. HbA1c testing must follow National Glycohemoglobin Standardization Program (NGSP) standards.
  9. Subject has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
  10. Pump therapy for greater than 6 months prior to screening (with or without CGM experience)
  11. Subject must have a companion or caregiver available at night for the duration of the study period who resides (or will live) in in the same building (or home). A companion or caregiver should also be available during exercise challenges in the same building, home or location (if not at home). This requirement may be verified by subject report at screening visit.
  12. Subject willing to upload data from the study pump, must have Internet access and a computer system that meets the requirements for uploading the study pump
  13. If subject has celiac disease, it has been adequately treated as determined by the investigator
  14. Subject is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)

    • Humalog™* (insulin lispro injection)
    • NovoLog™* (insulin aspart)
  15. Subjects with history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist
  16. Subjects with the 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist

    a. Cardiovascular risk factors include:

    • Age >35 years
    • Type 1 diabetes of >15 years' duration
    • Presence of any additional risk factor for coronary artery disease
    • Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)
    • Presence of peripheral vascular disease
    • Presence of autonomic neuropathy
  17. Subjects with history of cardiovascular event 1 year or more from the time of screening must have a stress test within 6 months prior to screening or during run in period. If subject fails stress test, participation is allowed if there is clearance from a cardiologist

Exclusion Criteria:

  1. Subject has a history of 1 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to Screening:

    1. Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization)
    2. Coma
    3. Seizures
  2. Subject has been hospitalized or has visited the ER in the 6 months prior to Screening resulting in a primary diagnosis of uncontrolled diabetes
  3. Subject has had Diabetic Ketoacidosis (DKA) in the 6 months prior to Screening.
  4. Subject has Hypoglycemia Unawareness, as measured by the Gold questionnaire (Gold, MacLeod et al. 1994) at Screening
  5. Subject is unable to tolerate tape adhesive in the area of sensor placement
  6. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
  7. Women of child-bearing potential who have a positive pregnancy test at Screening or plan to become pregnant during the course of the study
  8. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
  9. Subject has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  10. Subject is being treated for hyperthyroidism at time of Screening
  11. Subject has a diagnosis of adrenal insufficiency
  12. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of Screening, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study
  13. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
  14. Subject is currently abusing illicit drugs
  15. Subject is currently abusing marijuana
  16. Subject is currently abusing prescription drugs
  17. Subject is currently abusing alcohol
  18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of Screening
  19. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator
  20. Subject has elective surgery planned that requires general anesthesia during the course of the study
  21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of Screening
  22. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation
  23. Subject diagnosed with current eating disorder such as anorexia or bulimia
  24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia
  25. Subject has a hematocrit that is below the normal reference range of lab used.
  26. Subject is on dialysis
  27. Subject has serum creatinine of >2 mg/dL.
  28. Research staff involved with the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03959423


Contacts
Layout table for location contacts
Contact: Thomas Troub 818.576.3142 thomas.troub@medtronic.com
Contact: Melissa Vella melissa.vella@medtronic.com

Locations
Layout table for location information
United States, Arkansas
Arkansas Diabetes and Endocrinology Center Active, not recruiting
Little Rock, Arkansas, United States, 72211
United States, California
Scripps Whittier Diabetes Institute Active, not recruiting
La Jolla, California, United States, 92037
SoCal Diabetes Recruiting
Torrance, California, United States, 90505
Contact: Mary Halvorson    310-962-1808    halvorson@socaldiabetes.com   
Principal Investigator: Kevin Kaiserman, MD         
Diablo Clinical Research Active, not recruiting
Walnut Creek, California, United States, 94598
United States, Colorado
Barbara Davis Center - Adults Active, not recruiting
Aurora, Colorado, United States, 80045
Barbara Davis Center - Pediatric Recruiting
Aurora, Colorado, United States, 80045
Contact: Emily Boranian    303-724-4608    emily.boranian@ucdenver.edu   
Principal Investigator: Robert Slover, MD         
United States, Connecticut
Yale Diabetes Research Program Recruiting
New Haven, Connecticut, United States, 06511
Contact: Lori Carria    203-737-3595    lori.carria@yale.edu   
Principal Investigator: Jenn Sherr, MD         
United States, Florida
University of South Florida Recruiting
Tampa, Florida, United States, 33613
Contact: Janet Rodriguez    813-974-5499    janetrodriguez@health.usf.edu   
Principal Investigator: Dorothy Shulman, MD         
United States, Georgia
Atlanta Diabetes Associates Recruiting
Atlanta, Georgia, United States, 30318
Contact: Natalie Gruber    404-355-4393    mailto:trials@atlantadiabetes.com   
Principal Investigator: Bruce Bode, MD         
Southeastern Endocrine Active, not recruiting
Roswell, Georgia, United States, 30076
United States, Idaho
Rocky Mountain Diabetes Center Recruiting
Idaho Falls, Idaho, United States, 83404
Contact: Joann Malone    208-528-9650    joann@idahomed.com   
Principal Investigator: David Liljenquist, MD         
United States, Minnesota
International Diabetes Center Recruiting
Minneapolis, Minnesota, United States, 55416
Contact: Jamie Hyatt    952-993-9668    jamie.hyatt@parknicollet.com   
Principal Investigator: Anders Carlson, MD         
United States, Texas
Texas Endocrinology Active, not recruiting
Austin, Texas, United States, 78681
Diabetes and Glandular Disease Clinic Active, not recruiting
San Antonio, Texas, United States, 78229
United States, Washington
Rainier Clinical Research Active, not recruiting
Renton, Washington, United States, 98057
Sponsors and Collaborators
Medtronic Diabetes

Layout table for additonal information
Responsible Party: Medtronic Diabetes
ClinicalTrials.gov Identifier: NCT03959423     History of Changes
Other Study ID Numbers: CIP321
First Posted: May 22, 2019    Key Record Dates
Last Update Posted: September 24, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs